for anti-Ro/SSA and/or anti-La/SSB antibodies with HCQ during pregnancy. This is based on early and limited data and the low risk profile of HCQ. Retrospective studies demonstrate that in pregnant women with a prior child with cardiac NLE who take HCQ, there is a lower risk of the current fetus developing CHB For pregnant women with anti-Ro/SSA and/or anti-La/ SSB antibodies and fetal first-or second-degree heart block shown on echocardiography, we conditionally recommend treatment with oral